0001877990-24-000002.txt : 20240411 0001877990-24-000002.hdr.sgml : 20240411 20240411100247 ACCESSION NUMBER: 0001877990-24-000002 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240411 DATE AS OF CHANGE: 20240411 EFFECTIVENESS DATE: 20240411 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Praesidia Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001877990 ORGANIZATION NAME: IRS NUMBER: 870985466 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-509890 FILM NUMBER: 24837363 BUSINESS ADDRESS: STREET 1: 1167 MASSACHUSETTS AVE. CITY: ARLINGTON STATE: MA ZIP: 02476 BUSINESS PHONE: 6692459489 MAIL ADDRESS: STREET 1: 1167 MASSACHUSETTS AVE. CITY: ARLINGTON STATE: MA ZIP: 02476 D/A 1 primary_doc.xml X0708 D/A LIVE 0001877990 Praesidia Biotherapeutics, Inc. 1167 MASSACHUSETTS AVE. ARLINGTON MA MASSACHUSETTS 02476 6179775445 DELAWARE None None Corporation true 2021 Sohang Chatterjee 1167 Massachusetts Ave. Arlington MA MASSACHUSETTS 02476 Executive Officer Director Pradip Majumder 1167 Massachusetts Ave. Arlington MA MASSACHUSETTS 02476 Executive Officer Martin Lehr 1167 Massachusetts Ave. Arlington MA MASSACHUSETTS 02476 Director Shawn Titcomb 275 Commercial Blvd., Suite 333 Lauderdale by the Sea FL FLORIDA 33308 Director Biotechnology Decline to Disclose 06b true 0001877990-24-000001 2024-03-25 false true false 100000 Wilmington Capital Securities, LLC 133839 None None 275 Commercial Blvd. Suite 333 Lauderdale by the Sea FL FLORIDA 33308 AL ALABAMA AZ ARIZONA CA CALIFORNIA CO COLORADO FL FLORIDA IL ILLINOIS IN INDIANA MD MARYLAND MO MISSOURI MT MONTANA NJ NEW JERSEY NY NEW YORK PA PENNSYLVANIA TX TEXAS true 15000000 5000000 10000000 false 1 310000 true 0 The amount payable will depend on the amount sold and the composition of the investors. 0 true Proceeds of the offering will be used for for research and development, trial design and regulatory filings, manufacturing working capital and general corporate purposes and potentially for the acquisition of, or investment in, complementary businesses. false Praesidia Biotherapeutics, Inc. Sohang Chatterjee Sohang Chatterjee Chief Executive Officer 2024-04-11